Delving into the Latest Updates on Travoprost/Timolol Maleate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

DuoTrav APS, DuoTrav BAK, DuoTrav PQ

+ [11]

Target

PTGFR x β-adrenoceptors

Mechanism

PTGFR agonists(Prostanoid FP receptor agonists), β-adrenoceptors antagonists(Beta adrenergic receptors antagonists)

Therapeutic Areas

Eye Diseases

Active Indication

GlaucomaGlaucoma, Open-AngleOcular Hypertension

Inactive Indication-

Originator Organization

Alcon AG

Active Organization

Novartis AGNovartis Europharm Ltd.

Novartis Pharmaceuticals Corp.

Inactive Organization

Alcon Research Ltd.

Drug Highest PhaseApproved

First Approval Date

EU (23 Apr 2006),

Glaucoma, Open-AngleOcular Hypertension

Regulation-

Login to view timeline

Structure

Molecular FormulaC39H59F3N4O9S

InChIKeyKJNUGXGYVXURJB-DDANCUEQSA-N

CAS Registry874755-80-3

The purpose of this study is to assess efficacy and tolerability of changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-free) from prior Xalacom® or Ganfort® fixed combination pharmacotherapy in patients with open-angle glaucoma or ocular hypertension with uncontrolled intraocular pressure (IOP).

Start Date01 Jun 2012

Sponsor / Collaborator

Alcon Research Ltd.

100 Clinical Results associated with Travoprost/Timolol Maleate

Login to view more data

100 Translational Medicine associated with Travoprost/Timolol Maleate

Login to view more data

100 Patents (Medical) associated with Travoprost/Timolol Maleate

Login to view more data

70

Literatures (Medical) associated with Travoprost/Timolol Maleate

01 Aug 2024·VACCINE

Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus

Article

Author: Luo, Ping ; Zhang, Yi ; Cheng, Xin ; Wu, Meilin ; Wang, Yi ; Li, Yuhang ; Gu, Jiang ; He, Qinggang ; Li, Xiaoyan ; Chen, Yuan ; Wan, Jiqing

The conventional inactivated tetanus toxin plays an instrumental role in preventing tetanus. Nevertheless, the challenges associated with its production process, the potential for adverse reactions, and reduced effectiveness in vulnerable populations such as neonates and the elderly rise the need for a novel tetanus toxin vaccine. Recombinant subunit vaccine offer a viable solution, and the tetanus toxin fragment C (TTFC) is emerging as a promising candidate. In this study, through spontaneous isopeptide bond formation we conjugated the recombinant TTFC to self-assembled mi3 nanoparticle, which derived from an optimized KDPG aldolase, and generated the TTFC-mi3 protein nanoparticle vaccine. We found that TTFC-mi3 is stable, uniform spherical nanoparticles. Comparing with the free TTFC alone, TTFC-mi3 enhances the uptake and subsequent activation of dendric cells (DCs). In addition, a single dose of adjuvant-free TTFC-mi3 elicited a more rapid and potent protective immunity in mice. Moreover, TTFC-mi3 is of favorable safety in vitro and in vivo. Our findings indicate that TTFC-mi3 is a rapid-response, non-aluminum-adjuvanted vaccine against tetanus.

05 Sep 2022·Journal of epidemiologyQ3 · MEDICINE

Association of the Time to First Cigarette and the Prevalence of Chronic Respiratory Diseases in Chinese Elderly Population

Q3 · MEDICINE

ArticleOA

Author: Lou, Yiling ; Jiang, Heng ; Guo, Yingying ; Tian, Qingfeng ; Cao, Shiyi ; Gan, Yong ; Wang, Chao ; Zhu, Yi ; Lu, Zuxun

BACKGROUND:

Increasing number of studies have suggested the time to first cigarette after waking (TTFC) have significant positive effect on respiratory diseases. However, few of them focused on the Chinese population. This study aims to estimate the impact of TTFC on the prevalence of chronic respiratory diseases (CRD) in Chinese elderly and explore the association in different sub-populations.

METHODS:

Cross-sectional data of demographic characteristics, living environment, smoking-related variables, and CRD were drawn from the Chinese Longitudinal Healthy Longevity Survey in 2018. Multivariate stepwise logistic regression analyses were conducted to examine the association of the TTFC with the prevalence of CRD.

RESULTS:

This study includes 13,208 subjects aged 52 years and older, with a mean age of 85.3 years. Of them, 3,779 participants were ex- or current smokers (44.9% had the TTFC ≤30 minutes, 55.1% >30 minutes) and 1,492 had suffered from CRD. Compared with non-smokers, participants with TTFC ≤30 minutes seemed to have higher prevalence of CRD (OR 1.97; 95% CI, 1.65-2.35) than those with TTFC >30 minutes (OR 1.70; 95% CI, 1.44-2.00), although the difference was statistically insignificant (P_interaction = 0.12). Compared with TTFC >30 minutes, TTFC ≤30 minutes could drive a higher prevalence of CRD among female participants, those aged 90 years and older, urban residents, and ex-smokers (P_interaction < 0.05).

CONCLUSION:

Shorter TTFC relates to higher prevalences of CRD in Chinese older females, those aged 90 years and older, urban residents, and ex-smokers. Delaying TTFC might partially reduce its detrimental impact on respiratory disease in these specific subpopulations.

01 Dec 2020·Microbial cell factoriesQ2 · ENGINEERING & TECHNOLOGY

A probiotic treatment increases the immune response induced by the nasal delivery of spore-adsorbed TTFC

Q2 · ENGINEERING & TECHNOLOGY

ArticleOA

Author: Baccigalupi, Loredana ; Isticato, Rachele ; Mazzoli, Arianna ; Santos, Francisco Denis S ; Iossa, Susanna ; Ricca, Ezio ; Maia, Ana Raquel ; Saggese, Anella ; Leite, Fabio

Abstract:

Background:

Spore-forming bacteria of the Bacillus genus are widely used probiotics known to exert their beneficial effects also through the stimulation of the host immune response. The oral delivery of B. toyonensis spores has been shown to improve the immune response to a parenterally administered viral antigen in mice, suggesting that probiotics may increase the efficiency of systemic vaccines. We used the C fragment of the tetanus toxin (TTFC) as a model antigen to evaluate whether a treatment with B. toyonensis spores affected the immune response to a mucosal antigen.

Results:

Purified TTFC was given to mice by the nasal route either as a free protein or adsorbed to B. subtilis spores, a mucosal vaccine delivery system proved effective with several antigens, including TTFC. Spore adsorption was extremely efficient and TTFC was shown to be exposed on the spore surface. Spore-adsorbed TTFC was more efficient than the free antigen in inducing an immune response and the probiotic treatment improved the response, increasing the production of TTFC-specific secretory immunoglobin A (sIgA) and causing a faster production of serum IgG. The analysis of the induced cytokines indicated that also the cellular immune response was increased by the probiotic treatment. A 16S RNA-based analysis of the gut microbial composition did not show dramatic differences due to the probiotic treatment. However, the abundance of members of the Ruminiclostridium 6 genus was found to correlate with the increased immune response of animals immunized with the spore-adsorbed antigen and treated with the probiotic.

Conclusion:

Our results indicate that B. toyonensis spores significantly contribute to the humoral and cellular responses elicited by a mucosal immunization with spore-adsorbed TTFC, pointing to the probiotic treatment as an alternative to the use of adjuvants for mucosal vaccinations.

100 Deals associated with Travoprost/Timolol Maleate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	S01ED51	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	JP	Novartis Pharmaceuticals Corp.	16 Apr 2010
Glaucoma, Open-Angle	EU	Novartis Europharm Ltd.	23 Apr 2006
Glaucoma, Open-Angle	IS	Novartis Europharm Ltd.	23 Apr 2006
Glaucoma, Open-Angle	LI	Novartis Europharm Ltd.	23 Apr 2006
Glaucoma, Open-Angle	NO	Novartis Europharm Ltd.	23 Apr 2006
Ocular Hypertension	EU	Novartis Europharm Ltd.	23 Apr 2006
Ocular Hypertension	IS	Novartis Europharm Ltd.	23 Apr 2006
Ocular Hypertension	LI	Novartis Europharm Ltd.	23 Apr 2006
Ocular Hypertension	NO	Novartis Europharm Ltd.	23 Apr 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02730871 (CTgov)	Phase 4	Glaucoma, Open-Angle	173	Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension+Travoprost 0.004%/timolol 0.5% solution (Simbrinza + Duotrav)	eqfjkajdta(kttcbjjwga) = nmwbenlbzz mrulewwoom (cedozwumur, diwviixfmy - maimnowauz) View more	-	17 May 2019
				Brinzolamide/brimonidine vehicle+Travoprost 0.004%/timolol 0.5% solution (Vehicle + Duotrav)	eqfjkajdta(kttcbjjwga) = rpgqfsmjiq mrulewwoom (cedozwumur, qtxggqfubw - zgxzlsbfpg) View more
NCT02003391 (Pubmed \| J Ophthalmol) Manual	Phase 4	Ocular Hypertension \| Glaucoma, Open-Angle	156	Travoprost+Timolol	brchjjxinp(ucpmoceuft) = bjqczvacjl qcfqjrhlls (qfrmxsftga, 3.1) View more	Positive	01 Jan 2017
				beta-blocker monotherapy+Travoprost+Timolol	brchjjxinp(ucpmoceuft) = wztfybncti qcfqjrhlls (qfrmxsftga, 3.1) View more
NCT02003391 (CTgov)	Phase 4	Glaucoma, Open-Angle	157	Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution (DuoTrav)	uaufidzzrv(msturiurzb) = kqwdhlhzpl jfnwmtielw (aqdzoincrr, swadxizcav - zcdbillmpw) View more	-	08 Aug 2016
				Beta-blocker monotherapy+Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution (Beta-blocker)	uaufidzzrv(msturiurzb) = ovknwlwpyu jfnwmtielw (aqdzoincrr, tzrzcytwiw - bfschbmypo) View more
NCT01547598 (CTgov)	Phase 4	Glaucoma, Open-Angle	135	Bimatoprost ophthalmic solution 0.01%+travoprost ophthalmic solution 0.004% (LUMIGAN® RC)	opicwscxok(tnkebxqzuv) = omsvhfavfz msumnbksnn (pbawzgsmte, hmjcbjiqbw - ysyjsbneep) View more	-	15 Aug 2014
				travoprost ophthalmic solution 0.004%+travoprost 0.004% / timolol 0.5% combination ophthalmic solution (DuoTrav®)	opicwscxok(tnkebxqzuv) = yffgwiccbm msumnbksnn (pbawzgsmte, vdrvbempki - jomjzcsbbv) View more
ARVO2014	Not Applicable	Glaucoma	50	PQ-TTFC	oysdwserao(bmuxvqdhms) = juibgtvwqc mnkrkusxvb (lojbhvhulm ) View more	Positive	01 Apr 2014
NCT01327599 (CTgov)	Phase 4	Glaucoma-Related Pigment Dispersion Syndrome	60	Travoprost 0.004%+Timolol 0.5% ophthalmic solution	yqcngdsjyc(bziakarget) = hxeowpalop huboqjsfub (mbmnyvokai, lrmfjotnkc - qxlimrqmht) View more	-	10 Jan 2014
NCT01336569 (CTgov)	Phase 4	Glaucoma, Open-Angle	50	Travoprost 0.004%/timolol maleate 0.5% fixed combination	dxclwdqnyq(solzisuinw) = lxbfwmzsrx fildipxmyw (erysubairw, ghgwomushr - wstqscyohk) View more	-	08 Jul 2013
NCT00508469 (CTgov)	Phase 4	Glaucoma, Open-Angle	102	Travalert Dosing Aid+Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) (Travalert With Travoprost/Timolol Fixed Combination)	pxhqigrgmg(oshrqgeqlc) = tbyitobwlt jwaqdpukpa (lajvncaamq, dhwdoqoxvx - fwvmwzxdfn) View more	-	12 Jul 2012
				Travalert Dosing Aid+Timolol 0.05% eye drops+Travoprost 0.004% eye drops (Travalert With Travoprost and Timolol)	pxhqigrgmg(oshrqgeqlc) = pnrceymafo jwaqdpukpa (lajvncaamq, fjzwvjevsn - mqykwgbcyu) View more
NCT00887029 (ARVO2010)	Phase 4	Glaucoma, Open-Angle	-	Travoprost-Timolol Fixed-Combination	gedmhittpm(gkqzftsvbv) = wdbcqtoanp pczywszkna (ocymjojlsl ) View more	-	01 Apr 2010
				Latanoprost-Timolol Fixed-Combination	gedmhittpm(gkqzftsvbv) = ytukpkrfnz pczywszkna (ocymjojlsl ) View more
ARVO2010	Not Applicable	Glaucoma	45	Travoprost/timolol	pzjfflrxfe(rafxpnesnx) = nsofwwqxps rfahgbvbtp (xvoboioekk ) View more	-	01 Apr 2010
				Glaucoma patients treated with bimatoprost/timolol	pzjfflrxfe(rafxpnesnx) = lcjogyrqfh rfahgbvbtp (xvoboioekk ) View more